| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 01/14/2004 | EP1379628A2 Kinases and phosphatases sequences, and use thereof |
| 01/14/2004 | EP1379523A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 01/14/2004 | EP1379507A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS |
| 01/14/2004 | EP1379504A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors |
| 01/14/2004 | EP1379503A1 Pyrrolidine sulfonamides |
| 01/14/2004 | EP1379262A1 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |
| 01/14/2004 | EP1379260A2 Methods for treating the inflammatory component of a brain disorder |
| 01/14/2004 | EP1379246A1 Nociceptin analogs |
| 01/14/2004 | EP1379237A2 Pyrrolidine sulfonamides |
| 01/14/2004 | CN1468307A Anti-dual integrin antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468246A Hydroxyesters of 7-desmethylrapamycin |
| 01/14/2004 | CN1468222A N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3 receptor antagonists |
| 01/13/2004 | US6677359 N-substituted glycine derivatives |
| 01/13/2004 | US6677355 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 01/08/2004 | WO2004003164A2 Methods of organ regeneration |
| 01/08/2004 | WO2004002983A2 Therapeutic piperazine derivatives useful for treating pain |
| 01/08/2004 | WO2004002961A1 Caspase inhibitors and uses thereof |
| 01/08/2004 | WO2004002533A1 Stable liquid parenteral parecoxib formulation |
| 01/08/2004 | WO2004002424A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | WO2003087174A3 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 01/08/2004 | WO2003070969A3 RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/08/2004 | WO2003047618A3 Immunotherapeutic methods and systems |
| 01/08/2004 | WO2003020257A3 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| 01/08/2004 | WO2002079448A3 G-protein coupled receptors |
| 01/08/2004 | WO2002068650B1 Modified and stabilized gdf propeptides and uses thereof |
| 01/08/2004 | WO2002046225A3 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 01/08/2004 | US20040006242 Immunomodulatory compounds and method of use thereof |
| 01/08/2004 | US20040006092 Amidine derivatives for treating amyloidosis |
| 01/08/2004 | US20040006080 Chemical compounds |
| 01/08/2004 | US20040006078 For therapy of autoimmune diseases, asthma, osteoporosis, atherosclerosis, Alzheimer's disease |
| 01/08/2004 | US20040006066 Ring fused pyrazole derivatives as CRF antagonists |
| 01/08/2004 | US20040006063 Dipeptide derivatives |
| 01/08/2004 | US20040005630 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| 01/08/2004 | US20040005576 Comprises polypeptides for diagnosing, prognosing and preventing cancer, nervous system, developmental and metabolic disorders |
| 01/08/2004 | US20040005367 Methods of treating necrotizing enterocolitis |
| 01/08/2004 | US20040005316 Use of HMG fragments as anti-inflammatory agents |
| 01/08/2004 | US20040005298 Compositions and methods for restoring immune responsiveness in patients with immunological defects |
| 01/08/2004 | DE10227269A1 Thiazolderivate Thiazole derivatives |
| 01/08/2004 | CA2844639A1 Method for the treatment of multiple sclerosis |
| 01/08/2004 | CA2493646A1 Caspase inhibitors and uses thereof |
| 01/08/2004 | CA2490411A1 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | CA2489376A1 Methods of organ regeneration |
| 01/08/2004 | CA2488526A1 Stable liquid parenteral parecoxib formulation |
| 01/07/2004 | EP1377601A2 Type b botulism toxin inhibitors |
| 01/07/2004 | EP1377593A2 2-amino-propanol derivatives |
| 01/07/2004 | EP1377590A1 Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor |
| 01/07/2004 | EP1377587A1 Protein phosphate inhibitors |
| 01/07/2004 | EP1377580A2 Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor |
| 01/07/2004 | EP1377572A1 Isoxaxole derivatives as inhibitors of src and other protein kinases |
| 01/07/2004 | EP1377567A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 01/07/2004 | EP1377282A2 Aryl-n-cyanoguanidines and methods related thereto |
| 01/07/2004 | EP1289997B1 Macrolides |
| 01/07/2004 | CN1466575A Quinolene derivatives as anti-inflammation agents |
| 01/07/2004 | CN1466467A Pharmaceutical composition and method for treating hypogonadism |
| 01/07/2004 | CN1133427C Solid oral dosage forms of valsartan |
| 01/02/2004 | EP1374886A2 Treatment of neuromuscular disorders and conditions with different botulinum serotype |
| 01/02/2004 | EP1373517A2 Human kinases |
| 01/02/2004 | EP1373503A2 Neurotrophic factors |
| 01/02/2004 | EP1373489A2 Human dual specificity protein phosphatase 7-like protein |
| 01/02/2004 | EP1373319A2 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders |
| 01/02/2004 | EP1373317A2 Nuclear hormone receptor ligand binding domains |
| 01/02/2004 | EP1373315A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373313A2 Proteins and nucleic acids encoding same |
| 01/02/2004 | EP1373306A2 Cytoskeletion-associated proteins |
| 01/02/2004 | EP1373258A1 Ether derivatives useful as inhibitors of pde4 isozymes |
| 01/02/2004 | EP1373257A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/02/2004 | EP1373242A1 Dimeric isoflavones |
| 01/02/2004 | EP1373233A1 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 01/02/2004 | EP1373223A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 01/02/2004 | EP1373158A2 Additives for building industry obtained from by-products and process for their production |
| 01/02/2004 | EP1372696A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/02/2004 | EP1372695A2 Cell damage inhibitor |
| 01/02/2004 | EP1372690A2 93870, a human g-protein coupled receptor and uses therefor |
| 01/02/2004 | EP1372681A1 Biologically active chloroform fraction of an extract obtained from a mangrove plant salvadora persica l |
| 01/02/2004 | EP1372680A1 Biologically active aqueous fraction of an extract obtained from a mangrove plant salvadora persica l |
| 01/02/2004 | EP1372635A1 Use of creatine for the amelioration of oxidative stress |
| 01/02/2004 | EP1372626A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 01/01/2004 | US20040002525 Obesity; osteoporosis |
| 01/01/2004 | US20040002511 Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators |
| 01/01/2004 | US20040002493 Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient |
| 01/01/2004 | US20040002482 Androgen pharmaceutical composition and method for treating depression |
| 01/01/2004 | US20040002439 Human voltage gated sodium channel beta1A subunit and methods of use |
| 01/01/2004 | US20040002134 Novel nucleic acid sequences encoding human KIAA0768 protein-like and human protein PRO228-like polypeptides |
| 01/01/2004 | US20040002088 Identification and isolation of novel DNA and to the recombinant production of polypeptides having sequence similarity to Glial Cell line-derived Neurotrophic Factor Receptor (GDNFR) |
| 12/31/2003 | WO2004001069A2 Compositions and methods for detecting pathologies affecting neuromuscular transmission |
| 12/31/2003 | WO2004000846A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 12/31/2003 | WO2004000839A1 Thiazole derivatives as phosphodiesterase iv inhibitors |
| 12/31/2003 | WO2004000786A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
| 12/31/2003 | WO2004000333A1 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives |
| 12/31/2003 | WO2004000324A1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines |
| 12/31/2003 | WO2003082893A8 Theraputic methods and uses of sapogenins and their derivatives |
| 12/31/2003 | WO2003072704A3 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 12/31/2003 | WO2003072055A3 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors |
| 12/31/2003 | WO2003063758A3 Bicyclic cb2 cannabinoid receptor ligands |
| 12/31/2003 | WO2003059269A3 Acridone inhibitors of impdh enzyme |
| 12/31/2003 | WO2003055916A3 Adiponectin fragments and conjugates |
| 12/31/2003 | WO2003055912A3 Secreted proteins |
| 12/31/2003 | WO2003020759A9 A caspase- 8 binding protein, its preparation and use |
| 12/31/2003 | WO2003010286A9 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 12/31/2003 | WO2002060378A3 Substituted aryl compounds as cyclooxygenase-2 selective inhibitors, compositions and methods of use |